Patients with neovascular age-related macular degeneration who have responded poorly to anti-VEGF monotherapy may require an average of nine injections of faricimab before improvement is seen.
“Our message is, ‘Don’t give up, and manage these patients’ expectations accordingly,’” Judy Chen, MD, of West Coast Retina Medical Group, said at the American Society of Retina Specialists annual meeting.
Phase 3 clinical trials of Vabysmo (faricimab, Genentech), which was FDA approved for the treatment of wet AMD in January 2022, enrolled only treatment-naive